| 04 Jun, 06:13 pm | — | … | Aurobindo Pharma Limited has informed the Exchange regarding a press release dated Jun 04, 2026, titled "Aurobindo Pharma receives final US FDA approval for Tofacitinib Tablets, 5 mg and 10 mg". | nse |
| 03 Jun, 05:43 pm | — | … | Aurobindo Pharma Limited has informed the Exchange regarding a press release dated Jun 03, 2026, titled "Aurobindo Pharma Inaugurates TheraNym - Pioneering India s Large-Scale Biologics Contract Manufacturing Facility". | nse |
| 03 Jun, 05:38 pm | — | … | Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 27 May, 06:23 pm | — | … | Aurobindo Pharma Limited has informed the Exchange about Transcript | nse |
| 27 May, 06:14 pm | — | … | Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | bse |
| 24 May, 05:38 pm | — | … | Aurobindo Pharma Limited has informed the Exchange about Classification of Unit-I of Eugia Pharma Specialities Limited, wholly owned subsidiary of the Company as OAI. | nse |
| 22 May, 12:35 pm | — | … | Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Acquisition | bse |
| 22 May, 12:33 pm | — | … | Aurobindo Pharma Limited has informed the Exchange about Acquisition | nse |
| 21 May, 10:42 pm | — | … | Aurobindo Pharma Ltd - 524804 - Financial Results For The Year Ended March 31, 2026. | bse |
| 21 May, 09:05 pm | — | … | Aurobindo Pharma Limited has informed the Exchange regarding Reappointment of Ernst & Young LLP as Internal Auditors of the company w.e.f. Jun 01, 2026. | nse |
| 21 May, 09:05 pm | — | … | Aurobindo Pharma Ltd - 524804 - Intimation Of Appointment Of Internal Auditor | bse |
| 21 May, 09:02 pm | — | … | Aurobindo Pharma Limited has informed the Exchange regarding Appointment of RPR & Associates as Secretarial Auditor of the company w.e.f. May 21, 2026. | nse |
| 21 May, 08:53 pm | — | … | Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Cessation | bse |
| 21 May, 08:51 pm | — | … | Aurobindo Pharma Limited has informed the Exchange regarding Cessation of MRR Assocaites as Other of the company w.e.f. May 22, 2026. | nse |
| 21 May, 08:48 pm | — | … | Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation | bse |
| 21 May, 08:47 pm | — | … | Aurobindo Pharma Limited has informed the Exchange about Investor Presentation | nse |
| 21 May, 08:45 pm | — | … | Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 21 May, 08:43 pm | — | … | Aurobindo Pharma Limited has informed the Exchange regarding a press release dated May 21, 2026, titled "Press Release on Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2026.". | nse |
| 21 May, 07:43 pm | — | … | Aurobindo Pharma Ltd - 524804 - Board Meeting Outcome for Outcome Of Board Meeting | bse |
| 21 May, 07:40 pm | — | … | Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. | nse |
| 16 May, 09:42 pm | — | … | Aurobindo Pharma Limited has informed the Exchange about General Updates | nse |
| 16 May, 09:40 pm | — | … | Aurobindo Pharma Ltd - 524804 - Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 | bse |
| 16 May, 10:03 am | — | … | Aurobindo Pharma Ltd - 524804 - Curateq Biologics Receives CDSCO Marketing Authorisation (Form CT 23) For Bevqolva® (Bevacizumab Biosimilar) | bse |
| 16 May, 09:50 am | — | … | Aurobindo Pharma Limited has informed the Exchange about General Updates | nse |
| 15 May, 07:03 pm | — | … | Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Closure of Buy Back | bse |
| 15 May, 06:59 pm | — | … | Aurobindo Pharma Limited has informed the Exchange regarding Closure of Buy Back with effect from May 15, 2026 | nse |
| 14 May, 04:03 pm | — | … | Aurobindo Pharma Limited has informed the Exchange about schedule of Earnings Call to be held on May 22, 2026 at 8:30 AM (IST) on Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2026. | nse |
| 12 May, 03:58 pm | — | … | Aurobindo Pharma Ltd - 524804 - Board Meeting Intimation for Consider And Approve Inter Alia, The Standalone & Consolidated Audited Financial Results Of The Company For The Fourth Quarter And Financial Year Ended March 31, 2026 | bse |
| 08 May, 04:55 pm | — | … | Aurobindo Pharma Limited has submitted Copy of Newspaper Publication with regard to post buyback public advertisement. | nse |
| 06 May, 09:13 am | — | … | Aurobindo Pharma Limited has informed the Exchange about classification of Unit-VII of Aurobindo Pharma Limited, as Voluntary Action Indicated (VAI) | nse |
| 04 May, 06:12 pm | — | … | Aurobindo Pharma Limited has informed the Exchange about resignation of Dr. Sanjay Chaturvedi, CEO of Apitoria Pharma Private Limited, wholly owned subsidiary of the Company. | nse |
| 01 May, 01:58 pm | — | … | Aurobindo Pharma Limited has informed the Exchange that CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the Company Secures Health Canada NOC for Bevqolva Bevacizumab Biosimilar | nse |
| 30 Apr, 05:10 pm | — | … | Aurobindo Pharma Limited has informed the Exchange about Retirement of Mr. N. Ravikiran, Chief Business Officer, Emerging Markets, a Senior Management person of the Company. | nse |
| 30 Apr, 05:01 pm | — | … | Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Change in Management | bse |
| 24 Apr, 04:30 pm | — | … | Aurobindo Pharma Ltd - 524804 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | bse |
| 21 Apr, 04:03 pm | — | … | Aurobindo Pharma Limited has informed the Exchange about Buyback | nse |
| 21 Apr, 04:00 pm | — | … | Aurobindo Pharma Ltd - 524804 - Letter Of Offer For Buyback Of Up To 54,23,728 Fully Paid-Up Equity Shares Of The Company | bse |
| 17 Apr, 06:34 pm | — | … | Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 17, 2026, titled "Aurobindo Pharma receives USFDA approval for Dextromethorphan Polistirex Extended-Release Oral Suspension, 30 mg/5 mL (OTC)". | nse |
| 17 Apr, 06:31 pm | — | … | Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 17 Apr, 10:40 am | — | … | Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 17, 2026, titled "Aurobindo Pharma receives USFDA approval for Glycerol Phenylbutyrate Oral Liquid,1.1 grams per mL". | nse |
| 17 Apr, 10:37 am | — | … | Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 15 Apr, 04:07 pm | — | … | Aurobindo Pharma Limited has informed the Exchange about expanding existing CMO operations with Merck Sharpe & Dohme Singapore Trading Pte. Ltd by TheraNym Biologics Private Limited, a subsidiary of the Company | nse |
| 08 Apr, 11:41 am | — | … | Aurobindo Pharma Limited has informed the Exchange about submission of copy of Public Announcement pertaining to the Buyback published in newspapers on April 8, 2026 | nse |
| 07 Apr, 06:29 pm | — | … | Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 07 Apr, 06:24 pm | — | … | Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 07 Apr, 06:18 pm | — | … | Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 07, 2026, titled "Aurobindo Pharma receives USFDA approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets". | nse |
| 07 Apr, 06:14 pm | — | … | Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 07, 2026, titled "Aurobindo Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg". | nse |
| 06 Apr, 04:04 pm | — | … | Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 06 Apr, 04:02 pm | — | … | Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 06, 2026, titled "Press Release - CuraTeQ Biologics Announces Positive Top-Line Results for Phase 3 Study of Omalizumab Biosimilar BP11". | nse |
| 06 Apr, 08:58 am | — | … | Aurobindo Pharma Limited has informed the Exchange that Record date for the purpose of Buyback is 17-Apr-2026. | nse |